EAST SYRACUSE, N.Y. (AP) – Bristol-Myers Squibb Co. plans to invest $100 million on its campus here to make next generation drugs.
The investment marks a change in Bristol’s strategy. Four years ago, the company said it would use the facilities to make small amounts of drugs to be used in clinical trials.
About $40 million of the company’s investment will go to laboratories, $18 million to warehouses and storage, and the rest to infrastructure upgrades, said Ken Dauria, senior director of manufacturing operations in East Syracuse.
“The corporation has a little bit different strategy now,” Dauria said. “It’s a bridge strategy.”
Last August, the company announced it will close its 61-year-old bulk antibiotic facility in East Syracuse and cut 120 positions.
—
Information from: The Post-Standard, http://www.syracuse.com
AP-ES-01-23-05 1411EST
Send questions/comments to the editors.
Success. Please wait for the page to reload. If the page does not reload within 5 seconds, please refresh the page.
Enter your email and password to access comments.
Hi, to comment on stories you must . This profile is in addition to your subscription and website login.
Already have a commenting profile? .
Invalid username/password.
Please check your email to confirm and complete your registration.
Only subscribers are eligible to post comments. Please subscribe or login first for digital access. Here’s why.
Use the form below to reset your password. When you've submitted your account email, we will send an email with a reset code.